FUNGICYTE 150 Capsule is a highly effective antifungal formulation containing 150 mg of fluconazole, a synthetic triazole-class antifungal agent known for its broad-spectrum activity against fungal pathogens. It is indicated for the treatment of systemic and superficial fungal infections caused by Candida species, Cryptococcus, and other susceptible fungi. This product is frequently prescribed for the management of vaginal candidiasis, both acute and recurrent, as well as for fungal infections of the mouth, throat, esophagus, lungs, urinary tract, and blood. It may also be used in immunocompromised individuals, such as HIV-infected patients or those undergoing chemotherapy, to prevent fungal infections.
Fluconazole, the active pharmaceutical ingredient in FUNGICYTE 150 Capsule, exerts its antifungal action by selectively inhibiting fungal cytochrome P450 enzyme 14α-demethylase. This inhibition disrupts the synthesis of ergosterol, a key structural component of the fungal cell membrane, leading to cell membrane damage and ultimately fungal cell death. Unlike many other antifungal agents, fluconazole demonstrates excellent oral bioavailability and is well absorbed from the gastrointestinal tract, making it a preferred option in outpatient and inpatient care.
One of the most widely recognized benefits of FUNGICYTE 150 Capsule is its convenient single-dose therapy, particularly for vaginal candidiasis, where a one-time oral dose can effectively clear the infection. This dosage convenience improves patient compliance and reduces the risk of incomplete treatment. In more severe or systemic infections, such as cryptococcal meningitis or disseminated candidiasis, the capsule may be used as part of a longer treatment regimen under physician supervision.
FUNGICYTE 150 is also used as a prophylactic agent in individuals at high risk of fungal infections, including those undergoing bone marrow transplantation or long-term immunosuppressive therapy. It demonstrates excellent tissue penetration, including into the cerebrospinal fluid, making it particularly useful for treating central nervous system infections like cryptococcal meningitis. Its pharmacokinetics are favorable, with a long half-life that supports once-daily dosing and predictable plasma concentrations.
Patients using FUNGICYTE 150 Capsule typically tolerate the treatment well. Common side effects, when they occur, include headache, nausea, abdominal pain, diarrhea, dizziness, and transient liver enzyme elevations. Rarely, severe skin reactions or hepatotoxicity may be reported, especially in patients with pre-existing liver dysfunction or in those on prolonged therapy. Therefore, liver function monitoring is advised in such cases.
Drug interactions may occur, particularly with agents metabolized through the cytochrome P450 pathway, including anticoagulants like warfarin, certain antidiabetic drugs, immunosuppressants such as cyclosporine, and some antiepileptics. Medical professionals should carefully assess the patient's medication history before initiating treatment with FUNGICYTE 150 to avoid unwanted interactions and optimize therapeutic outcomes.
The product is manufactured using high-quality excipients and complies with Good Manufacturing Practices (GMP) and international pharmacopeial standards. Each capsule is packaged to maintain stability, efficacy, and protection from moisture and light. It is available in tamper-evident packaging, ensuring safety and hygiene throughout the product's shelf life.
FUNGICYTE 150 Capsule can be prescribed as monotherapy or in conjunction with other antifungal agents depending on the severity, location, and type of fungal infection. It plays a vital role in modern antifungal therapy due to its ease of administration, reliable efficacy, and wide spectrum of activity. Healthcare professionals across specialties—gynecology, internal medicine, infectious disease, and oncology—frequently rely on this formulation for both curative and preventive antifungal management.
In conclusion, FUNGICYTE 150 Capsule stands out as a versatile and clinically effective antifungal agent, offering rapid symptom relief, excellent patient adherence, and a proven safety record. It is a valuable component of any pharmaceutical portfolio, serving essential therapeutic needs in both primary and specialty care settings, and addressing fungal infections with precision and reliability.
Description provided by bluepill express.
FIEO Registered
Export Ready
